Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas

Human Pathology

Volumn 37, Issue 11, 2006, Pages 1414-1425

  Osada, Ryosuke ^a   Horiuchi, Akiko ^a   Kikuchi, Norihiko ^a   Ohira, Satoshi ^a   Ota, Masao ^a   Katsuyama, Yoshihiko ^b   Konishi, Ikuo ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Neuropilins; Ovarian cancer; Semaphorin; VEGF

Indexed keywords

NEUROPILIN 1; NEUROPILIN 2; SEMAPHORIN; SEMAPHORIN 3B; SEMAPHORIN 3F; UNCLASSIFIED DRUG; VASCULOTROPIN;

ALLELE; ANGIOGENESIS; ARTICLE; BENIGN TUMOR; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; EPITHELIUM; FEMALE; GENE EXPRESSION; GENE LOCUS; GENE LOSS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROVASCULATURE; OVARY CARCINOMA; PROGNOSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; NEUROPILIN-1; NEUROPILIN-2; OVARIAN NEOPLASMS; PROGNOSIS; SEMAPHORINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33750069768     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2006.04.031     Document Type: Article

References (42)

1. Ozols R.F., Rubin S.C., Thomas G.M., et al. Epithelial ovarian cancer. In: Hoskins W.J., Perez C.A., and Young R.C. (Eds). Principles and practice of gynecologic oncology (2000), Lippincott Williams & Wilkins, Philadelphia 981-1057
2. Mutch D.G., and Williams S. Biology of epithelial ovarian cancer. Clin Obstet Gynecol 37 (1994) 406-422
3. Dvorak H.F., Brown L.F., Detmar M., et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146 (1995) 1029-1039
4. Boocock C.A., Charnock-Jones D.S., Sharkey A.M., et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87 (1995) 506-516
5. Paley P.J., Staskus K.A., Gebhard K., et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80 (1997) 98-106
6. Yamamoto S., Konishi I., Mandai M., et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 76 (1997) 1221-1227
7. Bamberger E.S., and Perrett C.W. Angiogenesis in epithelian ovarian cancer. Mol Pathol 55 (2002) 348-359
8. Gasparini G., Bonoldi E., Viale G., et al. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer 69 (1996) 205-211
9. Obermair A., Wasicky R., Kaider A., et al. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer. Cancer Lett 138 (1999) 175-182
10. Ogawa S., Kaku T., Kobayashi H., et al. Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma. Cancer Lett 176 (2002) 111-118
11. Takahashi T., Nakamura F., Jin Z., et al. Semaphorins A and E act as antagonists of neuropilin-1 and agonists of neuropilin-2 receptors. Nat Neurosci 1 (1998) 487-493
12. Soker S., Takashima S., Miao H.Q., et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92 (1998) 735-745
13. Larrivee B., and Karsan A. Signaling pathways induced by vascular endothelial growth factor. (review). Int J Mol Med 5 (2000) 447-456
14. Latil A., Bieche I., Pesche S., et al. VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int J Cancer 89 (2000) 167-171
15. Parikh A.A., Fan F., Liu W.B., et al. Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. Am J Pathol 164 (2004) 2139-2151
16. Wey J.S., Gray M.J., Fan F., et al. Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J Cancer 93 (2005) 233-241
17. Kolodkin A.L., Matthes D.J., and Goodman C.S. The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules. Cell 75 (1993) 1389-1399
18. Luo Y., Raible D., and Raper J.A. Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell 75 (1993) 217-227
19. Miao H.Q., Soker S., Feiner L., et al. Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 146 (1999) 233-242
20. Bagnard D., Vaillant C., Khuth S.T., et al. Semaphorin 3A-vascular endothelial growth factor-165 balance mediates migration and apoptosis of neural progenitor cells by the recruitment of shared receptor. J Neurosci 21 (2001) 3332-3341
21. Sekido Y., Bader S., Latif F., et al. Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns. Proc Natl Acad Sci U S A 93 (1996) 4120-4125
22. Kuroki T., Trapasso F., Yendamuri S., et al. Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancer. Cancer Res 63 (2003) 3352-3355
23. Senchenko V.N., Liu J., Loginov W., et al. Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas. Oncogene 23 (2004) 5719-5728
24. Bachelder R.E., Lipscomb E.A., Lin X., et al. Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. Cancer Res 63 (2003) 5230-5233
25. Scully R.E., Young R.H., and Clement P.B. Tumors of the ovary and maldeveloped gonads, fallopian tube, and broad ligament. In: Rosai J. (Ed). Atlas of tumor pathology, 3rd series, Fascicle 23 (1998), Armed Forces Institute of Pathology, Washington (DC) 51-168
26. Silverberg S.G. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 19 (2000) 7-15
27. Brambilla E., Constantin B., Drabkin H., et al. Semaphorin SEMA3F localization in malignant human lung and cell lines: a suggested role in cell adhesion and cell migration. Am J Pathol 156 (2000) 939-950
28. Lantuejoul S., Constantin B., Drabkin H., et al. Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. J Pathol 200 (2003) 336-347
29. Weidner N., Semple J.P., Welch W.R., et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324 (1991) 1-8
30. Bosari S., Lee A.K., DeLellis R.A., et al. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23 (1992) 755-761
31. Mandai M., Konishi I., Kuroda H., et al. Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology. Hum Pathol 29 (1998) 34-40
32. Zhai Y.L., Nikaido T., Orii A., et al. Frequent occurrence of loss of heterozygosity among tumor suppressor genes in uterine leiomyosarcoma. Gynecol Oncol 75 (1999) 453-459
33. Wang C., Horiuchi A., Imai T., et al. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol 202 (2004) 215-223
34. Kusy S., Potiron V., Zeng C., et al. Promoter characterization of Semaphorin SEMA3F, a tumor suppressor gene. Biochim Biophys Acta 1730 (2005) 66-76
35. Bielenberg D.R., Hida Y., Shimizu A., et al. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest 114 (2004) 1260-1271
36. Tse C., Xiang R.H., Bracht T., et al. Human Semaphorin 3B (SEMA3B) located at chromosome 3p21.3 suppresses tumor formation in an adenocarcinoma cell line. Cancer Res 62 (2002) 542-546
37. Kessler O., Shraga-Heled N., Lange T., et al. Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res 64 (2004) 1008-1015
38. Catalano A., Caprari P., Rodilossi S., et al. Cross-talk between vascular endothelial growth factor and semaphorin-3A pathway in the regulation of normal and malignant mesothelial cell proliferation. FASEB J 18 (2004) 358-360
39. Wang L., Zeng H., Wang P., et al. Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. J Biol Chem 278 (2003) 48848-48860
40. Barr M.P., Byrne A.M., Duffy A.M., et al. A peptide corresponding to the neuropilin-1-binding site on VEGF (165) induces apoptosis of neuropilin-1-expressing breast tumour cells. Br J Cancer 92 (2005) 328-333
41. Stephenson J.M., Banerjee S., Saxena N.K., et al. Neuropilin-1 is differentially expressed in myoepithelial cells and vascular smooth muscle cells in preneoplastic and neoplastic human breast: a possible marker for the progression of breast cancer. Int J Cancer 101 (2002) 409-414
42. Osada H., Tokunaga T., Nishi M., et al. Overexpression of the neuropilin 1 (NRP1) gene correlated with poor prognosis in human glioma. Anticancer Res 2B (2004) 547-552